Free Trial
NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

Vertex Pharmaceuticals logo
$445.20 +3.90 (+0.88%)
As of 04:00 PM Eastern

About Vertex Pharmaceuticals Stock (NASDAQ:VRTX)

Key Stats

Today's Range
$439.23
$446.45
50-Day Range
$421.16
$509.50
52-Week Range
$377.85
$519.88
Volume
1.11 million shs
Average Volume
1.42 million shs
Market Capitalization
$114.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$511.62
Consensus Rating
Moderate Buy

Company Overview

Vertex Pharmaceuticals is a global biotechnology company dedicated to discovering, developing and commercializing innovative therapies for serious diseases. Since its founding in 1989 by Dr. Joshua Boger, the company has been at the forefront of translating cutting-edge science into medicines that address underlying causes rather than just symptoms. Headquartered in Boston, Vertex maintains research and development sites and commercial operations across North America, Europe, Australia and Asia.

Vertex’s core business revolves around cystic fibrosis (CF), where its portfolio of small-molecule therapies—including ivacaftor, lumacaftor, tezacaftor and elexacaftor—has transformed treatment paradigms for patients with specific genetic mutations. Beyond CF, the company has broadened its pipeline to include programs in sickle cell disease, beta-thalassemia, pain management and APOL1-mediated kidney disease, leveraging approaches such as gene editing, messenger RNA technology and novel ion channel modulators.

Research partnerships and collaborations are central to Vertex’s strategy. The company has teamed with academic institutions and industry leaders in gene therapy and CRISPR technology to accelerate development timelines and expand its reach into new therapeutic areas. Manufacturing facilities in North America and Europe support both clinical supply and commercial production, ensuring scalability as programs advance.

Under the leadership of President and Chief Executive Officer Reshma Kewalramani, Vertex continues to invest heavily in R&D, with a focus on precision medicine and genetic disease research. The company’s long-term vision emphasizes sustainable growth through innovation, strategic alliances and a patient-centric approach to drug development.

AI Generated. May Contain Errors.

Vertex Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

VRTX MarketRank™: 

Vertex Pharmaceuticals scored higher than 94% of companies evaluated by MarketBeat, and ranked 72nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 13 buy ratings, 14 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Vertex Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Vertex Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Vertex Pharmaceuticals are expected to grow by 12.03% in the coming year, from $15.63 to $17.51 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vertex Pharmaceuticals is -113.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vertex Pharmaceuticals is -113.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vertex Pharmaceuticals has a P/B Ratio of 6.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Vertex Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.57% of the float of Vertex Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vertex Pharmaceuticals has recently decreased by 8.62%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Vertex Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Vertex Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.57% of the float of Vertex Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vertex Pharmaceuticals has recently decreased by 8.62%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Vertex Pharmaceuticals has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 44 news articles for Vertex Pharmaceuticals this week, compared to 29 articles on an average week.
  • Search Interest

    31 people have searched for VRTX on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.
  • MarketBeat Follows

    Only 16 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -16% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,084.00 in company stock.

  • Percentage Held by Insiders

    Only 0.20% of the stock of Vertex Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vertex Pharmaceuticals' insider trading history.
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Equities Analysts Offer Predictions for VRTX Q3 Earnings
See More Headlines

VRTX Stock Analysis - Frequently Asked Questions

Vertex Pharmaceuticals' stock was trading at $402.70 at the beginning of 2025. Since then, VRTX stock has increased by 10.4% and is now trading at $444.55.
View the best growth stocks for 2025 here
.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its quarterly earnings results on Monday, May, 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing analysts' consensus estimates of $4.29 by $0.23. The company's quarterly revenue was up 2.6% on a year-over-year basis.
Read the conference call transcript
.

Vertex Pharmaceuticals subsidiaries include these companies: V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and more.

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include Salesforce (CRM), Chevron (CVX), QUALCOMM (QCOM), AbbVie (ABBV), Home Depot (HD), CocaCola (KO) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
5/05/2025
Today
6/30/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VRTX
Employees
6,100
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$511.62
High Stock Price Target
$586.00
Low Stock Price Target
$420.00
Potential Upside/Downside
+15.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.54
Research Coverage
28 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
28.23
P/E Growth
N/A
Net Income
-$535.60 million
Pretax Margin
-2.70%

Debt

Sales & Book Value

Annual Sales
$11.02 billion
Price / Cash Flow
N/A
Book Value
$63.72 per share
Price / Book
6.93

Miscellaneous

Free Float
256,283,000
Market Cap
$113.33 billion
Optionable
Optionable
Beta
0.42

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:VRTX) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners